Date:11/19/2009

d) Assets Current assets: Cash and cash equivalents $1,367 $12,726 Short-term investments 3,125 7,256 Grant and other receivables 320 207 Prepaid expenses and other current assets 128 289 --- --- Total current assets 4,940 20,478 Deferred offering costs 1,034 - Property and equipment, net 681 918 Intangible assets, net - 60 Restricted cash 193 193 Other assets 62 32 -- -- Total assets $6,910 $21,681 ====== ======= Liabilities, convertible preferred stock and shareholders' equity (deficit) Current liabilities: Accounts payable $1,530 $1,229 Accrued expenses 3,739 3,764 Preferred stock warrant liability 902 1,780 Deferred revenue 1,019 232 Current portion of notes payable 4,750 16,556 ----- ------ Total current liabilities 11,940 23,561 Notes payable, less current portion 9,244 118 Commitments and contingencies Convertible preferred stock: Issued and outstanding shares-11,514,506 at September 30, 2009 (unaudited) and 11,392,057 at December 31, 2008; Liquidation preference of $93,284 at September 30, 2009 (unaudited) and
'/>"/>

SOURCE Omeros Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
9. Omeros Commences Initial Public Offering of Common Stock
10. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation